Diffuse mesothelioma
Pretreatment volume-based 18F-FDG PET/CT parameters as prognostic indicators in malignant peritoneal mesothelioma patients
Japanese Journal of Radiology 2026 March 21 [Link] Kazuhiro Kitajima, Kosuke Matsuda, Hiroyuki Yokoyama, Toshiyuki Minami, Akifumi Nakamura, Kozo Kuribayashi, Takashi Kijima, Koichiro Yamakado Abstract Objective: This study was conducted to examine relationships of pretreatment volume-based quantitative 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) parameters with overall survival (OS) in malignant peritoneal mesothelioma (MPeM) patients.…
Read MorePrognostic value and clinical significance of tumoral PD-L1 and stromal α-SMA expression in diffuse pleural mesothelioma
Neoplasma 2026 February [Link] Yeqi Sun, Lan Li, Lei Cai, Jihua Yang, Jun Qian, Fajiu Wang, Lifeng Wang Abstract Diffuse pleural mesothelioma (PM) is a rare malignant neoplasm with an extremely poor prognosis. Prognostic assessment remains challenging, highlighting the urgent need for reliable biomarkers to guide precise and effective therapy. Programmed death ligand 1 (PD-L1)…
Read MoreThe Accuracy of Video-Assisted Thoracic Surgery Pleural Biopsy in Patients with Suspected Diffuse Pleural Mesothelioma: A Real-Life Study
Journal of Clinical Medicine 2025 December 20 [Link] Ludovica Balsamo, Enrica Migliore, Eleonora Della Beffa, Luisa Delsedime, Paolo Olivo Lausi, Daniela Di Cuonzo, Filippo Lococo, Paraskevas Lyberis, Dario Mirabelli, Mauro Giulio Papotti, Enrico Ruffini, Francesco Guerrera Abstract Background: The heritage of occupational and environmental asbestos exposure in Piedmont, Italy, has resulted in an enduring diffuse…
Read MoreDeterminants of Response to Immune Checkpoint Blockade in Pleural Mesothelioma: Molecular, Immunological, and Clinical Perspectives
Cancers 2025 December 17 [Link] Martina Delsignore, Gaia Cassinari, Simona Revello, Luigi Cerbone, Federica Grosso, Marcello Arsura, Chiara Porta Abstract Diffuse pleural mesothelioma (PM) is a rare thoracic malignancy with historically limited treatment options and poor outcomes. Despite the recent breakthrough of dual immune checkpoint blockade (ICB)-notably the combination of anti-PD-1 and anti-CTLA-4 therapies-clinical responses…
Read MoreEfficacy and safety of PD-1/PD-L1 and CTLA-4 immune checkpoint inhibitors in the treatment of diffuse pleural mesothelioma: a systematic review and meta-analysis
Frontiers in Immunology 2025 September 2 [Link] Peiyuan Sun, Dandan Song, Ning Ma, Shufu Hou, Lei Liu, Jing Gao, Yanyan Tian Abstract Background: While clinical trials confirm the therapeutic value of PD-1/PD-L1 and CTLA-4 inhibitors in diffuse pleural mesothelioma, their real-world safety and efficacy profiles remain incompletely defined. This meta-analysis synthesizes clinical evidence to comprehensively…
Read MorePerioperative nivolumab or nivolumab plus ipilimumab in resectable diffuse pleural mesothelioma: a phase 2 trial and ctDNA analyses
Nature Medicine 2025 September 8 [Link] Joshua E Reuss, Paul K Lee, Reza J Mehran, Chen Hu, Suqi Ke, Amna Jamali, Mimi Najjar, Noushin Niknafs, Jaime Wehr, Ezgi Oner, Qiong Meng, Gavin Pereira, Samira Hosseini-Nami, Mark Sausen, Marianna Zahurak, Richard J Battafarano, Russell K Hales, Joseph Friedberg, Boris Sepesi, Julie S Deutsch, Tricia Cottrell, Janis…
Read MoreCo-Targeting BCL-xL with MCL-1 Induces Lethal Mitochondrial Dysfunction in Diffuse Mesothelioma
Molecular Cancer Therapeutics 2025 September 5 [Link] Yuan Xu, Cristian G Medina, Deborah R Surman, Lacey E Dobrolecki, Monica Vilchis, Maheshwari Ramineni, Susan G Hilsenbeck, Yanming Li, Naren Li, Siqi Wu, Jaylon C Aggison, Xi Chen, Yi Zhu, Ying H Shen, R Taylor Ripley Abstract Diffuse mesothelioma is a rare but highly aggressive and treatment-resistant…
Read MoreCDKN2A deletion is associated with immune desertification in diffuse pleural mesothelioma
Journal of Experimental & Clinical Cancer Research 2025 August 28 [Link] Federica Torricelli, Benedetta Donati, Veronica Manicardi, Mila Gugnoni, Francesca Reggiani, Gloria Manzotti, Pierluigi Di Chiaro, Cristian Ascione, Simonetta Piana, Riccardo Valli, Roberto Piro, Massimiliano Paci, Nicola Facciolongo, Filippo Lococo, Alessia Ciarrocchi Abstract Introduction: Diffuse Pleural Mesothelioma (DPM) is a rare and incurable cancer. Immune…
Read MoreIdentification of Cembrane Diterpenoids from Sinularia sp. That Reduce the Viability of Diffuse Pleural Mesothelioma Cell Lines
Journal of Natural Products 2025 August 25 [Link] Maria Orfanoudaki, Anam F Shaikh, Dongdong Wang, Vivek Singh, Lin Du, Jennifer A Wilson, Antony Wamiru, Ekaterina I Goncharova, Nathanael Pruett, Chuong D Hoang, Brice A P Wilson, Barry R O’Keefe Abstract Diffuse pleural mesothelioma (DPM) is a rare but aggressive late-onset cancer. A high-throughput screen of…
Read MoreIdentification of Cembrane Diterpenoids from Sinularia sp. That Reduce the Viability of Diffuse Pleural Mesothelioma Cell Lines
Journal of Natural Products 2025 August 25 [Link] Maria Orfanoudaki, Anam F Shaikh, Dongdong Wang, Vivek Singh, Lin Du, Jennifer A Wilson, Antony Wamiru, Ekaterina I Goncharova, Nathanael Pruett, Chuong D Hoang, Brice A P Wilson, Barry R O’Keefe Abstract Diffuse pleural mesothelioma (DPM) is a rare but aggressive late-onset cancer. A high-throughput screen of…
Read More
Skip to content